Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial

TL;DR

This study found that aniseed powder may help reduce gastrointestinal symptoms like abdominal pain and diarrhea in patients with mild COVID-19.

Contribution

The study is the first to evaluate aniseed powder as an add-on therapy for gastrointestinal symptoms in acute SARS-CoV-2 infection.

Findings

Aniseed powder significantly improved abdominal pain, anorexia, and diarrhea in COVID-19 patients.

Aniseed and placebo groups had similar rates of adverse events, with mild to moderate effects reported.

The findings suggest aniseed's active compound, trans-anethole, may have multiple therapeutic effects relevant to COVID-19.

Abstract

Background: Gastrointestinal symptoms are prevalent amongst patients with a confirmed diagnosis of COVID-19 and may be associated with an increased risk of disease severity. This trial aimed to evaluate the efficacy and safety of aniseed (Pimpinella anisum L.) powder as an add-on therapy to standard care for treating gastrointestinal symptoms experienced by adults with an acute SARS-CoV-2 infection.

Methods: The study was a randomized parallel-group double-blinded placebo-controlled add-on therapy trial. Adults with an acute SARS-CoV-2 infection who did not require hospitalization and reported at least one gastrointestinal symptom in the preceding 48 h were assigned to either the aniseed or placebo group in a 1:4 ratio. All 225 participants (45 in the aniseed group and 180 in the placebo group) were instructed to use 25 g of powdered aniseed or placebo twice daily for 2 weeks. The primary outcomes were the proportion of patients who experienced an improvement of at least one point in the symptom score after adjusting for age group, gender, and time. Backwards stepwise logistic regression was applied to calculate the risk ratios. The clinical symptoms and adverse events were assessed at the beginning, 1 week later, and at the end of the trial (week two).

Results: Participants in the aniseed group were significantly more likely to report symptom improvement for abdominal pain [adjusted risk ratio (RR):0.55; 95% confidence interval (CI): 0.46–0.72], anorexia (RR:0.62; 95% CI: 0.47–0.82), and diarrhea (RR:0.19; 95% CI: 0.12–0.30), but not nausea/vomiting (RR:0.87; 95% CI: 0.71–1.08) or bloating (RR:0.87; 95% CI: 0.72–1.05). Two participants in the aniseed group and three participants in the placebo group reported mild to moderate adverse events.

Conclusion: This study showed that 2 weeks of aniseed powder containing trans-anethole (87%–94%) may help improve abdominal pain, anorexia, and diarrhea in COVID-19 patients. The findings align with the known biological, multitargeted activity of P. anisum and trans-anethole, which includes inhibiting SARS-CoV-2 along with other anti-infective, anti-inflammatory, antioxidant, hepatoprotective, and anti-dysbiosis properties. Multicenter trials with larger sample sizes and longer follow-up are warranted to confirm these findings.

Clinical Trial Registration: Iranian Registry of Clinical Trials (IRCT20120506009651N3).

Figures

CONSORT flowchart of participants.

Mean scores of gastrointestinal symptoms at the baseline, week 1, and week 2.

Tables

TABLE 1. Characteristics of participants.

Variable	Placebo group (n = 180)	Aniseed group (n = 45)	p-value
Mean age (years)	44.63 (SD 13.68)	40.96 (SD 10.70)	0.094
Less than 20	7 (3.8%)	1 (2.2%)	0.693
20 to 39	73 (40.6%)	21 (46.6%)
≥40	100 (55.6%)	23 (51.2%)
Gender
Male	113 (62.7%)	23 (51.2%)	0.152
Female	67 (37.2%)	22 (48.8%)
Ethnicity
Fars	170 (94.4%)	42 (93.3%)	0.775
Other	10 (5.6%)	3 (6.7%)
Education
Diploma and Less than diploma	84 (46.6%)	15 (33.4%)	0.107
More than diploma	96 (53.4%)	30 (66.6%)
Marital status
Single	60 (33.3%)	17 (37.7%)	0.574
Married	120 (66.7%)	28 (62.3%)
Smoker
No	125 (69.4%)	35 (77.7%)	0.270
Yes	55 (30.6%)	10 (22.3%)
Mean BMI
<30	154 (85.6%)	40 (88.9%)	0.562
≥30	26 (14.4%)	5 (11.1%)
Gastrointestinal symptoms
Anorexia severity score	2.06 (SD 0.98)	2.29 (SD 0.82)	0.150
Nausea & Vomiting severity score	2.07 (SD 0.98)	2.58 (SD 1.01)	0.002
Abdominal pain severity score	2.75 (SD 0.90)	3.0 (SD 0.67)	0.075
Bloating severity score	1.80 (SD 0.87)	2.54 (SD 1.01)	<0.001
Diarrhea frequency score	5.62 (SD 1.77)	5.83 (SD 1.11)	0.445

TABLE 2. Effect of aniseed product on risk of reducing gastrointestinal symptoms of COVID-19 patients.

Gastrointestinal symptom as outcome	Unadjusted RR to compare aniseed vs. placebo (95% CI)	Adjusted RR to compare aniseed vs. placebo (95% CI)	p-value
Abdominal Pain	0.57 (0.47, 0.76)	0.55 (0.46, 0.72)	<0.001
Anorexia	0.64 (0.51, 0.84)	0.62 (0.47, 0.82)	0.001
Nausea/vomiting	0.88 (0.72, 1.07)	0.87 (0.71, 1.08)	0.268
Diarrhea	0.21 (0.13, 0.30)	0.19 (0.12, 0.30)	<0.001
Bloating	0.84 (0.64, 1.02)	0.87 (0.72, 1.05)	0.153

Full text

Introduction

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At the beginning of the COVID-19 pandemic, symptoms associated with acute respiratory tract infections, such as fever and cough, were the primary focus. As the pandemic has progressed and new variants have emerged, there is increasing awareness of the extrapulmonary manifestations of the disease. Over 70 different clinical manifestations have been identified, of which 10 are gastrointestinal (Luo et al., 2022).

The presence of gastrointestinal (GI) symptoms may precede pulmonary involvement (Jin et al., 2020; Poggiali et al., 2020). Anorexia (12.9%), diarrhea (8.1%), nausea (6.7%), constipation (5.5%), melena (5.3%), abdominal pain (3.7%) and heartburn (3.6%) are estimated to be the most common (Luo et al., 2022). While the overall prevalence is probably less than 20% and may not differ from the general population prevalence rates for neonates, children or pregnant women (Zeng et al., 2022), GI manifestations appear to be associated with an increased risk of COVID-19 severity, especially the presence of abdominal pain (Menon et al., 2021; Zeng et al., 2022). Serious complications, such as gastrointestinal bleeding and small intestine necrosis, have also been reported (Pan et al., 2020; Menon et al., 2021). However, it is currently unclear whether GI manifestations are associated with an increased risk of death, as the findings from systematic reviews are mixed (Menon et al., 2021; Wang et al., 2022).

Clinical guidelines for COVID-19 management provide non-specific recommendations for treating GI symptoms, such as antipyretics for pain and rehydration for vomiting or diarrhea (WHO, 2021). Persian medicine (PM) represents a rich source of potentially beneficial phytomedicines for various GI disorders (Avicenna, 2005; Aghili Shirazi, 2008). One example is the fruit of Pimpinella anisum L. (anise), also known as aniseed, which is dried and ground into an edible powder (Sáfūf). PM describes aniseed as possessing a warm and dry temperament that has analgesic, anti-bloating, anti-colic, carminative, and astringent properties (Ibn-al-Nafis, 2008; Aghili Shirazi, 2009).

There are over 150 species of the Pimpinella genus throughout the world, each containing different metabolites depending on geographical location. Trans-anethole (76.9%–93.7%) is often the main metabolite found in aniseed essential oil (Akbar, 2020).

Clinical trials that support PM traditional claims include a randomized, three-arm, double-blind, clinical trial, which reported that 4 weeks of treatment with an enteric-coated capsule of anise oil was more effective at eradicating the clinical symptoms of irritable bowel syndrome than both the placebo and the Colpermin^®^ (peppermint oil) intervention (Mosaffa-Jahromi et al., 2016). In another double-blind, randomized controlled trial, aniseed powder was more effective than a placebo (corn starch) powder at relieving postprandial distress syndrome symptom severity (Ghoshegir et al., 2015). Aniseed and its essential oil are common food products widely used across the globe and are generally considered to be safe. Reassuringly, neither of the aforementioned trails reported any serious adverse effects (Ghoshegir et al., 2015; Mosaffa-Jahromi et al., 2016).

Although mortalities from COVID-19 have dropped, there has been an increase in the number of people infected with the virus in different regions and at different times (Ma et al., 2021). Considering the global burden of the disease and the troubling GI manifestations that can affect the treatment process and the disease severity, finding effective methods to prevent and treat GI symptoms is important. The prevalence and potential risks of GI manifestations in COVID-19, the paucity of evidence-based clinical recommendations for managing these manifestations, and the traditional and emerging scientific evidence of aniseed as a safe and effective intervention for other non-specific GI conditions prompted us to conduct this study. This clinical trial aimed to evaluate the efficacy and safety of aniseed (P. anisum L.) powder for treating gastrointestinal symptoms experienced by adults with an acute SARS-CoV-2 infection.

Methods

Study design and protocol registration

This study is a randomized, parallel-group, double-blind, placebo-controlled, add-on therapy trial that was conducted from May to August 2022 at Motahari Clinic, affiliated with Shiraz University of Medical Sciences, Shiraz, Iran. Ethical clearance was provided by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1400.859) in accordance with the Declaration of Helsinki. The study protocol was registered on 2022-04-04 in the Iranian Registry of Clinical Trials (IRCT20120506009651N3).

Following registration and prior to recruitment protocol changes were made for pragmatic reasons. The intervention dose was increased from 5 g to 25 g per sachet. Symptoms were scored on a scale of 1 to 4 rather than with a frequency scale. The inclusion criteria were changed to exclude hospitalized patients, and patients only needed to have one, rather than all of the gastrointestinal symptoms.

Primary and secondary outcomes

The efficacy outcomes were the proportion of patients who had an improvement of at least one point in the symptoms score including abdominal pain severity, anorexia severity, nausea and vomiting, bloating severity, and diarrhea frequency. Adverse events was the secondary outcome.

Outcome measures

The primary endpoint for each efficacy outcome was the proportion of participants with a decrease of at least one point in their symptom score at the end of 2 weeks of treatment, adjusting for intervention, age group, gender, time, and body mass index (BMI). The secondary endpoint for each efficacy outcome was the change in weekly mean symptom score over the 2 weeks, adjusting for baseline score, gender, age and BMI. The secondary endpoints for adverse events were the number of participants who experienced one or more adverse events and the number and types of adverse events.

Symptom severity scores were assessed using the gastrointestinal questions from the Pars Farsi Questionnaire. The validity and reliability of this questionnaire were previously confirmed in the Pars Cohort Study (Gandomkar et al., 2017). The frequency of diarrhea per day was also recorded using a categorical question. Symptoms were scored on a four-point Likert scale (1 = none/mild and 4 = very severe), which participants recorded on a form at baseline, the end of week 1, and at the end of the study. Participants were instructed to report any side effects or unexpected symptoms in an open-ended question on the form and to contact the researchers by telephone. The participant questionnaire forms were collected at the end of the study.

Intervention

Eligibility and enrollment of study participants were confirmed by internal medicine, gastroenterology, or infectious disease specialists at the Motahari Clinic. As an add-on therapy trial design, COVID-19 patients not requiring hospitalization were prescribed standard treatment according to the treatment protocols of the Iranian Ministry of Health (Rahmanzade et al., 2020). General recommendations regarding fluid intake, rest, nutrition, psychological support, and home oxygen therapy were provided to all patients. In addition, the participants were instructed to mix one 25 gr sachet of the intervention powder containing either the aniseed or a placebo, in 250 mL of water to be administered twice daily, 1 h after breakfast (9 a.m.) and lunch (3 p.m.), for 2 weeks.

Formulation of aniseed powder

The Pharmaceutics Laboratory of Shiraz School of Pharmacy was responsible for preparing the formulations. An oral powder formulation of aniseed was selected to facilitate optimal delivery to the GI system (Avicenna, 2005). Prior to grinding with an ultra-centrifugal electric mill, contaminating particles (soil, dust, etc.) were removed manually from the aniseeds. The aniseeds were then powdered and sieved using mesh size number 50. The obtained powder was sealed in polyethylene plastic bags and kept at 10°C until the quality control analysis at Shiraz University of Medical Sciences, school of pharmacy. After the quality was confirmed, the aniseed powder was mixed with rock candy powder (Sepahan Industrial Co., Iran) in a ratio of 2:1 and then sieved again using mesh size number 50. After assessing the particle size, pH, volumetric mass, moisture content, ash percentage, flow, and organoleptic characteristics, the product was packaged in sachets with a medicinal net weight of 25 gr (±5 gr), followed by a product weight confirmation test.

Formulation of placebo powder

To prepare the placebo powder, white wheat flour (Zar Macaron Industrial Co., Iran) and rock candy powder (Sepahan Industrial Co., Iran) were mixed in the same ratio mentioned above and packed in 25 g sachets. The drug and placebo were matched for packaging, color, and appearance, but not taste.

Identification and cultivation of anise plant

Aniseed is the fruit of P. anisum L., which is native to Iran. Samples of the fruit were purchased from three different sources (a local market in Shiraz city, a traditional medicine shop in Shiraz bazar, and a medicinal plant garden in School of Pharmacy, Shiraz); each sample was collected in Shiraz, Fars province, Iran [latitude and longitude coordinates are: 29.591768, 52.583698.] in summer 2021, and a herbarium of the entire plant was prepared. The plant was identified and confirmed by a plant species specialist (herbarium number: TP-772).

Standardization and quality control of aniseed powder

In addition to noting the appearance properties, the aniseed powder metabolites were identified and quantified based on the U.S., British, and European pharmacopeias. The anise essential oil in the powder was standardized using different methods, focusing on its main metabolite, trans-anethole (87%–94%) at the School of Pharmacy, Shiraz University of Medical Sciences. Trans-anethole is a key distinguishing metabolite found in aniseed (Ghosh et al., 2019).

Thin-layer chromatography analysis of anise essential oil and trans-anethole

The anise essential oil underwent thin-layer chromatography (TLC) using a mixture of ethyl acetate and methanol in a ratio of 19:1. Subsequently, the anise essential oil and trans-anethole were spotted on a TLC plate, both diluted in 5 mL dichloromethane, and the plates were dried. The resulting spots were visualized by spraying the trans-anethole detector on the samples. Afterwards, the plates were placed on a hot plate, causing the two corresponding spots to undergo derivatization with similar retention factors, indicating the similarity between the two compounds.

Gas chromatography analysis of anise essential oil and trans-anethole

The anise essential oil and pure trans-anethole were analyzed using a gas chromatography/flame ionization detector (GC/FID) apparatus. The analysis was conducted on a BRUKER gas chromatograph equipped with a 5CB capillary column and connected to an FID. Nitrogen was used as the carrier gas at a flow rate of 1 mL/min, and the split ratio was set at 1:100. The injector temperature was maintained at 250°C, while the detector temperature was set to 280°C. The column temperature was programmed to increase linearly from 60°C to 210°C at a rate of 5°C/min and then held at 210°C for 15 min. The retention time for both the anise essential oil and trans-anethole exhibited identical values.

Additionally, the essential oil profile of an anise oil sample was determined by utilizing chromatography/mass spectrometry (GC/MS). The analysis was performed using an Agilent 6,850 Series II instrument equipped with a fused silica HP-5 capillary column (30 m × 0.25 mm, 0.25 μm film thickness) and an Agilent Mass Selective Detector MSD 5973. The ionization voltage was set at 70 eV, the electron multiplier energy at 2,000 V, and the source temperature at 250°C. Mass spectra were scanned within the range of 35–450 amu at a scan time of 5 scans/s. The transfer line temperature was maintained at 295°C.

The identified components were established by comparing their mass spectra with those available in the Willey and Adams libraries. Additionally, the Kovats retention index and information reported in the literature were taken into consideration. Among the various components identified through GC/MS analysis, trans-anethole was specifically determined as the major compound in the essential oil of this collected sample.

Microbial limits testing

Microbial limits tests were conducted to determine the presence of microorganisms in the sample. These tests included counts of Gram-negative bacteria, Escherichia coli and Salmonella to assess the microbiological safety and quality of the sample. By performing these tests, it was evident that the overall microbial contamination was within the normal range, ensuring that the sample met the required standards for purity and safety.

Inclusion criteria

Included were patients who met the following criteria: 1) acute COVID-19 infections confirmed by a positive PCR test; 2) having at least one gastrointestinal symptom (e.g., nausea, vomiting, abdominal pain, diarrhea, anorexia, constipation) within 48 h before the examination; 3) mild to moderate lung involvement (less than 30% according to chest computed tomography scan) without the need for immediate hospitalization; 4) between 18 and 70 years of age; 5) available for subsequent evaluations during the study; 6) voluntary participation after signing the informed consent form.

Exclusion criteria

Excluded were patients with a history of 1) chronic gastrointestinal diseases (e.g., gastrointestinal reflux, hiatus hernia, peptic ulcer, irritable bowel syndrome, inflammatory bowel disease); 2) allergy to any kind of botanical drug product; 3) serious or critical conditions, such as congestive heart failure, kidney failure, or liver failure; 4) diabetes, thyroid disease, high blood pressure, or any other contraindications to the use of botanical drug products as determined by the researchers; 5) the presence of any venous thrombosis risk factors; 6) pregnant or breastfeeding women; 7) simultaneous participation in another clinical trial; 8) increasing severity of disease or need for hospitalization during the trial; or 9) use of treatments outside of the standard protocol for the treatment of COVID-19.

Randomization and allocation concealment

Restricted randomization, using random permuted blocks of five, with an allocation ratio of 1:4 was applied. A free online Saghaei random allocation software was used to generate a random sequence (https://mahmoodsaghaei.tripod.com/Softwares/randalloc.html). Each generated random sequence was recorded on a card by a research assistant who had no other role in the study. The card was then sealed within an envelope, and a three-digit serial number was recorded on the outer surface of each envelope. The envelopes were opened sequentially according to the order of participant enrollment, and participants were assigned to either the aniseed or placebo group. Another research assistant, was blinded to the group allocation, dispensed the interventions.

Blinding

To maintain blinding, participants, physicians, and personnel involved in executing the study procedure were unaware of the group allocation. Participants, physicians, and personnel involved in executing the study procedure were blinded to the group allocation. Blinding of study personnel, including those involved in data entry and preparing the data for analysis, was maintained until the database was locked. The codes were then opened by the supervisor of the research team.

Sample size

The sample size calculations were based on an anticipated prevalence of diarrhea in patients with COVID-19 of 49.5% (Fang et al., 2020), with 80% statistical power, 5% type 1 error, and a 50% greater impact for alleviating GI symptoms. Due to financial limitations, the ratio of participants in the experimental and control groups was set at 1:4. Initially, the sample size for the experimental group was calculated at 40 people, and then extended to 45, considering a 15% probability of dropout during the study. Hence, out of a total of 225 eligible patients, 45 were recruited in the experimental group, and 180 were recruited in the control group.

Statistical analysis

An intention to treat analysis was conducted. When comparing differences in baseline characteristics between the two groups, the independent t-test was used for continuous variables, and the chi-squared test was used for categorical variables. For multivariate analysis of the risk ratio and repeated measures analysis of change in mean symptom score over the 2 weeks, generalized estimating equation analysis was employed. The backward elimination technique with an elimination criterion of a p-value >0.3 was used to optimize the model. The following covariates were included in the full saturated model: intervention, age group, gender, time, and BMI. Stata software (version 11.2, Texas, United States) was used for statistical analysis. A p-value <0.05 was considered significant.

Results

Out of 327 adults who were assessed for eligibility, 225 were randomized into the placebo (n = 180) or aniseed (n = 45) intervention group (Figure 1). All participants received the allocated intervention, and no participants were lost to follow-up or excluded from the analysis. We had no missing outcome data for the 15 symptom items (i.e., 5 questions at baseline, week 1 and week 2).

CONSORT flowchart of participants.

The average age of the participants was 40.96 years (SD 10.70) in the aniseed group and 44.63 years (SD 13.68) in the placebo group (p = 0.094). Sixty percent of the participants were female. Although there were no significant differences in baseline mean anorexia severity (p = 0.150), abdominal pain severity (p = 0.075), or diarrhea frequency (p = 0.445) scores, both the mean nausea and vomiting severity score (p = 0.002) and mean bloating severity score (p < 0.001) were significantly lower in placebo group. The participant characteristics are summarized in Table 1.

After adjusting for age group, gender, BMI, and time, participants in the aniseed group were significantly more likely to report symptom improvements in abdominal pain (risk ratio (RR): 0.55; 95% confidence interval (CI): 0.46, 0.72), anorexia (RR: 0.62; 95% CI: 0.47, 0.82), and diarrhea (RR: 0.19; 95% CI: 0.12, 0.30) in patients with COVID-19 but, not significant effect on nausea/vomiting or bloating (Table 2).

The mean scores of GI symptoms at the beginning, end of week one, and end of the study (week two) are shown in Figure 2. After adjusting for mean baseline score, age group, gender, BMI and the change in weekly mean symptom score over the 2 weeks, participants in the aniseed group were significantly more likely to report symptom improvements in mean scores for abdominal pain (p < 0.001), anorexia (p = 0.001), diarrhea (p < 0.001).

Mean scores of gastrointestinal symptoms at the baseline, week 1, and week 2.

No serious adverse events were reported. In the aniseed group, two participants complained of mild throat itching, and one of mild thirst. In the placebo group, three participants complained of a mild cough, and two of moderate abdominal cramp. None of these participants stopped the intervention nor withdrew from the study.

Discussion

This study is novel in two aspects. Firstly, it investigated the effects of botanical drug on gastrointestinal symptoms experienced by patients with COVID-19 using a double-blinded, placebo-controlled add-on therapy trial study design. Secondly, it explored the efficacy of a popular PM botanical drug, aniseed (P. anisum L.), that has received little attention in the context of viral infections. Our results showed that daily consumption of the aniseed formulation significantly reduced three out of the five GI symptoms–abdominal pain, anorexia, and diarrhea. Furthermore, the formula was well tolerated and no dangerous or life-threatening adverse events were observed.

Although the current study is significant for the introduction of a new botanical drug metabolite to alleviate some common gastrointestinal symptoms in COVID-19 patients, it had certain limitations such as not recording the patients’ diet nor difference in taste of aniseed and placebo that may have impacted blinding, absence of molecule docking results, and lack of a long-term follow-up for the patients. Additionally, no statistical adjustments for multiple comparison were made, however, a Type 1 error is unlikely as the p-value was very small for all three significant differences in the primary endpoints.

Notwithstanding these limitations, given these positive findings, we explored the potential mechanisms by which P. anisum and some of its metabolites, especially trans-anethole, could have improved symptoms by suppressing the SARS-CoV-2 and/or intervening in the pathophysiological process of COVID-19.

Inhibition of SARS-CoV-2 proteins by aniseed–in silico studies

Some in silico studies showed the potential of P. anisum to inhibit the SARS-CoV-2 Spike (S) protein and the Chymotrypsin-like protease or main protease (3CL^PRO^ or M^PRO^). The receptor binding domain (RBD) of SARS-CoV-2 S glycoprotein binds to angiotensin-converting enzyme 2 (ACE-2) receptors of host cells to gain entry and replicate. ACE-2 receptors are abundantly expressed in human tissues, not only in the respiratory system (nasopharynx and bronchus), heart, kidneys, and male reproductive system, but also in the enterocytes of the small intestine, colon, and rectum, and gallbladder, and pancreas (Pontén et al., 2008). The expression of ACE-2 mRNA and protein in the gastrointestinal tract is 100 times higher than in the lungs (Hikmet et al., 2020). While the S protein allows attachment and viral entry into target cells, the 3CL^PRO^ is one of the proteins that cleave large polyproteins, and release replicative proteins that allow the process of viral transcription, translation, and replication. Drugs that can block the S protein and the 3CL^PRO^ are considered good drug candidates to fight viral infection. Thus, the gastrointestinal tract is a credible doorway for SARS-CoV-2 access.

Thus, these in silico studies show potential mechanisms by which P. anisum and its phytochemicals could directly inhibit SARS-CoV-2 replication and reduce COVID-19 gastrointestinal symptoms.

Antiviral properties of aniseed—in vitro studies

Although in vitro studies on the antiviral action of P. anisum and trans-anethole against RNA viruses are scarce, the water extract of P. anisum has demonstrated antiviral activity against herpes simplex (HSV-1 and HSV-2), cytomegalovirus (HCMV), and measles virus (Lee et al., 2011). In an in vitro study, trans-anethole (from star anise essential oil or Illicium verum) was one of the 6 tested metabolites that suppressed the HSV-1 infectivity by > 90% at a maximum noncytotoxic concentration. In this experiment, the herpes virus was incubated for 1 h with various concentrations of botanical drug metabolites before host infection. The authors concluded that the successful inhibiting metabolites directly inactivated the virus probably interfering with virion envelope structures or blocking structures that are necessary for cell entry (Astani et al., 2011).

Anti-inflammatory properties of aniseed

The invasion of SARS-CoV-2 into cells of the GI tract causes breakage of the mucosal barrier and promote the production of inflammatory factors (Yi et al., 2021). Studies have shown abnormal levels of cytokines and chemokines in patients with COVID-19 such as IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, M-CSF, G-CSF, GM-CSF, IP-10, IFN-γ, MCP-1, MIP 1-α, hepatocyte growth factor (HGF), TNF-α, and vascular endothelial growth factor (VEGF) (Costela-Ruiz et al., 2020). However, the cytokine and chemokine profile may vary depending on the COVID-19 14-day disease phase, disease severity, location where the infection started (respiratory or digestive system), and the section of the infected GI tract (Jiao et al., 2021). Natural agents that can modulate inflammation in the GI tract during the SARS-CoV-2 infection would likely contribute to symptom improvement.

The chemical structure of the P. anisum plant was previously investigated and reported in detail. The presence of trans-anethole as a main metabolite enables us to identify possible mechanisms to explain the beneficial effects of the aniseed formulation. In Yanarlia et al.'s study, P. anisum and its volatile essential oil metabolites demonstrated anti-inflammatory activity, reducing the expression level of pro-inflammatory cytokines IL-1 and IL-8 in the epithelial cells of the trachea and primary bronchi in an animal model of lipopolysaccharide-induced lung inflammation (Iannarelli et al., 2018). Another controlled study found that aqueous extract of aniseed significantly reduced the gene expression of IL-5 and IL-13 and the protein levels of inflammatory cytokines in the lung tissue of laboratory mice with allergic asthma treated (Dargahi et al., 2021).

Anti-inflammatory and gastroprotective effects of trans-anethole have also been demonstrated in experimental model via different mechanisms (Yi et al., 2021; da Rocha et al., 2023; Yu et al., 2022; Tong et al., 2023). These anti-inflammatory effects are similar in strength to those of indomethacin (Tas et al., 2006) and may also help explain the mechanism behind relieving gastrointestinal symptoms. For example, abdominal pain, as a probable predictor of severe COVID-19 (Hayashi et al., 2021), can be caused by the stimulation of sensory nerves (with an increase in cytokines and chemical inflammatory mediators) (Coates et al., 2013), and the anti-inflammatory effect of the P. anisum essential oil may impede this pathway. It has also been shown that myalgia caused by COVID-19 has an inflammatory basis (Hasan et al., 2021), and the anti-inflammatory effect of trans-anethole is also worth considering in this context. In addition, the analgesic effects of anise’s essential oil have been shown to be comparable to those of drugs like aspirin and morphine (Tas et al., 2006).

A recent cross-sectional study involving older adults identified inflammation to be as a major independent risk factor for reduced appetite (Sieske et al., 2019). Therefore, the anti-inflammatory metabolites of P. anisum may help explain the improvements in anorexia in our study. Diarrhea, another common gastrointestinal symptom in patients with COVID-19, was reduced significantly with the use of the aniseed formulation in the current study. This symptom may originate from inflammation of the intestinal cells (Sweetser, 2012), which would explain the therapeutic effect of the formulation, considering its anti-inflammatory properties. On the other hand, the lack of affecting bloating in this study may be due to the fact that compounds containing anti-inflammatory substances can cause or aggravate bloating (Suzuki et al., 2007). While strong glucocorticoids like dexamethasone offer mild anti-nausea/vomiting effects due to their anti-inflammatory function (Chu et al., 2014), P. anisum and its active metabolute (trans-anethole) are not among the strong anti-inflammatory substances compared to these metabolites. This may explain the observed ineffectiveness of the aniseed formulation in treating nausea/vomiting.

Hepatoprotective and antioxidant effects of aniseed

The COVID-19 infection can lead to liver damage, abnormal liver function, and elevated liver enzymes, with gastrointestinal and abdominal clinical manifestations (Ma et al., 2020). COVID-19-associated liver injury has been confirmed through autopsy and biopsy and the main findings are hepatic steatosis, mild lobular and portal inflammation, congestion/sinusoidal dilation, lobular necrosis, and cholestasis (Yang et al., 2023). COVID-19-related liver injury may be due to drug-induced liver injury, systemic inflammation, and hypoxia-ischemia reperfusion, but liver damage from a direct SARS-CoV-2 attack is uncertain (Zhong et al., 2020). Also, recent studies suggest that excessive production of reactive oxygen and nitrogen species (RONSs) and an unbalanced antioxidant-oxidant system play an important role in COVID-19 disease process (Suhail et al., 2020). Since ACE-2 receptors contribute to lowering oxidative stress which in turn modulates the binding affinity of both SARS-CoV-2 S protein and ACE-2, the authors concluded that, therapeutics that reduce oxidative stress could prevent viral binding to host cells and have a beneficial effect in the early stage of viral infection (Suhail et al., 2020). Moreover, it has been suggested that glutathione deficiency may be implicated in the pathogenesis of severe COVID-19 (Polonikov, 2020).

In a study investigating the effects of trans-anethole in hepatotoxicity associated with high doses of acetaminophen, this compound prevented the upregulation of proinflammatory mediators involved in the hepatotoxicity such as nitric oxide (NO), TNF, IL- α, MIP-1 α, and MCP-1 (da Rocha et al., 2017). In a murine research model, trans-anethole protected the liver against diabetes-induced hepatic injury by reducing blood glucose levels, liver enzyme activity, food and water intake, the intensity of weight loss, serum triglycerides, total cholesterol, low density lipoprotein, and increased high density lipoprotein (Samadi-Noshahr et al., 2021).

Also, in an in vitro and in vivo study, the researchers verified the hepatoprotective effects of n-hexane extracted from P. anisum against carbon tetrachloride-induced hepatotoxicity. N-hexane lowered serum transaminases levels, lactate dehydrogenase activity, liver histological changes, and cells death (in vitro and in vivo), and increased glutathione (GSH) and decreased thiobarbituric acid-reactive (in vitro) (Jamshidzadeh et al., 2015). The authors concluded that n-hexane extract of anise has hepatoprotective activity through its antioxidant metabolites. In fact, the water and ethanol extract of P. anisum seed exhibited antioxidant activity in all concentrations tested. Both extracts had strong free radicals, superoxide anion, hydrogen peroxide scavenging, and metal chelating activities when compared to control substances (Gülçın et al., 2003).

Action of aniseed on COVID-19 microbiome and gut epithelial barrier

Besides GI mucosal damage, the gastrointestinal microbiome can be greatly affected by the SARS-CoV-2 infection. When comparing the microbiome composition of COVID-19 patients and uninfected controls, the COVID-19 patients had a depletion of beneficial microorganisms that help maintain GI immune and barrier functions (Sun et al., 2022). There was also an increase in pathogenic species with significantly higher quantities in severe patients that tended to decrease when patients improved. The intestinal dysbiosis caused altered immune responses, gut barrier dysfunction, and an increase in circulating levels of lipopolysaccharide-binding protein in severe patients. Increased permeability of the intestinal epithelial lining allows viral translocation into the bloodstream and potential systemic dissemination (Sun et al., 2022). Also, shotgun metagenomic sequencing analyses detected an enrichment of opportunistic pathogens and depletion of beneficial commensals organisms in hospitalized COVID-19 patients which correlated with disease severity (Zuo et al., 2020). Interventions that can restore microbiome balance, protect epithelial lining, and modulate immune responses would likely help in this scenario.

Essential oil extracted from P. impinella species has been found to counteract both Gram-negative and Gram-positive bacteria (Nasır and Yabalak, 2021). In an animal study, anethole opposed E. coli K88, enriched the abundance of beneficial flora, protected intestinal barrier function, upregulated mucosal layer and tight junction proteins, reduced plasma concentrations of IL-1β and TNF-α (p < 0.1), and decreased the mRNA expression of TLR5, TLR9, MyD88, IL-1β, TNF-α, IL-6, and IL-10 (Yi et al., 2021). Also, the star anise (I. verum) essential oil, which also may contain a fair amount of trans-anethole was effective at killing beneficial and pathogenic organisms of the GI flora, although it was less active toward Lactobacilli than Bifidobacteria or potentially pathogenic organisms (Hawrelak et al., 2009). Thus, anethole-containing essential oils may have a modulatory effect on the gut microbiome and could assist in COVID-19 pathological process. Since diarrhea is a common symptom of COVID-19 and this symptom can also be attributed to intestinal dysbiosis, the improvement seen in our study could be partly explained by a beneficial action of P. anisum and its metabolites on the patients’ gut microbiome and intestinal epithelium barrier.

The potential effects of aniseed on the gut-lung axis in COVID-19

In a novel non-human primate model research, two types of SARS-CoV-2 inoculations were tested, intranasal and intragastric inoculations (Jiao et al., 2021). Interestingly, both separate inoculations caused infection, pathological changes, and viral shedding in the respiratory and digestive tissues (pneumonia and GI dysfunctions), induction of inflammatory cytokines, and gut barrier impairment. The intragastric inoculation induced a larger amount of inflammatory cytokines which may then spill over to the respiratory tissues via the bloodstream and lymphatic system. The authors concluded that GI inflammatory factors are a potential bridge for viral pathogenesis between the respiratory and GI systems (Astani et al., 2011). The gut-lung axis or the interplay between the respiratory mucosa and GI microbiota is under investigation. Changes in the gut microbiota density and diversity can affect lung immunity, and lung inflammation can lead to intestinal dysbiosis (de Oliveira et al., 2021). However, the precise mechanism by which the infection can disseminate from the gut to the lungs and vice-versa is still unknown.

Regardless, drugs that can act on both the respiratory and GI systems to modulate innate and humoral immunity, inflammation, gut microbiome, and gut barrier would likely be of great assistance in COVID-19. Traditional and evidence-based information shows that aniseed can be used for respiratory problems (e.g., asthma, bronchitis, bronchial secretions, cough, etc.) and digestive complaints (e.g., nausea, indigestion, flatulence, intestinal colic, constipation, etc.). Thus, we speculate that P. anisum and its metabolites are interesting drug candidates to address viral infections affecting the gastrointestinal system (Akbar, 2020; Nasır and Yabalak, 2021).

Prospective use of aniseed on long COVID-19

One study verified that while oropharyngeal SARS-CoV-2 shedding was absent at 4 months, there is evidence of fecal RNA shedding at 4 months (12.7% of participants) and 7 months (3.8%) after the diagnosis. The authors also found that GI symptoms (abdominal pain, nausea, and vomiting) are associated with fecal shedding (Natarajan et al., 2022). The prolonged viral shedding in the GI tract could be involved in the long-term infection and be one of the reasons for the systemic effects of long COVID-19 syndrome. Our current study evaluated 2 weeks of an aniseed formulation on the GI symptoms of COVID-19 patients with positive results. However, we theorize that aniseed formulations could be used for a longer period to protect tissues from damage and prevent viral dissemination from the GI tract to other organs through the gut lining.

Persian medicine and nutrition

As a holistic school of medicine, PM has a special approach to treating various diseases. In this approach, treatment is started with dietary instructions and lifestyle modifications, with pharmaceutical prescriptions given only if there is no proper response (Tafazoli et al., 2022). Adherence to PM-based treatments requires initial compliance with nutritional instructions and lifestyle guidelines, which are quite difficult to implement considering the pandemic nature of COVID-19 and its psychological burden on the patient and the patient’s family. In this process, the appropriate medicine is selected based on principles such as herbal temperament, disease temperament, etc. Since cold and wet are the predominant temperament in most GI symptoms associated with COVID-19 (e.g., diarrhea or bloating) (Pasalar et al., 2016), the warm and dry temperament cited for anise formulations in PM may aligns with its traditional applications.

Also, considering aniseed as a superfood with beneficial effects like antidiabetic and hypolipidemic ones (Shahrajabian et al., 2019), it may be conceived that long-standing aniseed consumption might ameliorate hazardous coexisting conditions such as diabetes or hyperlipidemia in COVID-19 patients. This may lead to better control of the disease and related GI manifestations.

Persian medicine and traditional Chinese medicine

There have been numerous clinical studies assessing the effectiveness of botanical drugs from Traditional Chinese Medicine (TCM) in alleviating gastrointestinal (GI) symptoms. For example, a systematic review and meta-analysis focusing on Chinese herbal medicine demonstrated non-beneficial effects in improving GI manifestations such as nausea, vomiting, anorexia, and diarrhea. These results may be attributed to variations in botanical drug metabolites, diverse mechanisms of action, and potential drug-herb interactions across different disciplines (Shi et al., 2021).

Conclusion

The results of our research revealed that an aniseed powder formulation containing trans-anethole (87%–94%) significantly improved abdominal pain, anorexia, and diarrhea in COVID-19 patients. Given the existing biological properties of P. anisum and trans-anethole, we theorize that symptom improvement could have been due to the multitargeted activity and protective mechanism in the GI system. P. anisum and its phytochemicals may act directly on the viral infection by inhibiting SARS-CoV-2 S protein and 3CL^PRO^, and could intervene in the COVID-19 pathological process through their anti-inflammatory, antioxidant and hepatoprotective properties, balancing COVID-19-associated dysbiosis, supporting the gut barrier, and promoting a dual therapeutic action in the respiratory and GI systems via the gut-lung axis. Therefore, P. anisum could be a safe and effective option for reducing GI symptoms associated with enteric SARS-CoV-2 infection. Larger studies with longer follow-up periods are recommended to confirm these findings and provide additional insights on effects of P. anisum on long COVID-19 and its mechanisms of action.